Impact and Mechanism of Depression on Cardio-cerebral Vascular Events and Arteriovenous Fistula Dysfunction in MHD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

286 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-01

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Depression is a common psychiatric disorder in patients on maintenance hemodialysis (MHD). It may contribute to poor prognosis in a number of ways, including its effect on platelet function. We aimed to investigate the impact and underlying mechanisms of depression on the occurrence of cardio-cerebral vascular events (CCVE) and dysfunction of arteriovenous fistula (DAVF) in MHD patients.

In this study, MHD patients were recruited and divided into depression and non-depression groups using the Hamilton Depression Scale (HAMD) in this prospective cohort study. Their clinical and laboratory indicators were collected and the occurrence of CCVE and DAVF were recorded through clinical follow-up, and analyzed, and the differences and possible influencing factors of CCVE and DAVF occurrence were assessed between the two groups of patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis

NCT00618475

End Stage Renal Disease Depression

COMPLETED NA

Morbidity and Mortality Among Dialysis Patients After Treatment for Depression

NCT00442429

Depression ESRD

UNKNOWN

Identifying and Treating Depression in Hemodialysis Patients

NCT03390933

Depression Hemodialysis-Induced Symptom

COMPLETED PHASE4

Intravenous Iron May Increase Depression Among Hemodialysis Patients

NCT03157050

Depression Hemodialysis Complication Iron Deficiency Anemia

COMPLETED

Electronic Training of Elderly Depression With Cognitive Impairment

NCT05588102

Geriatric Depression Cognitive Impairment

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardio-cerebral Vascular Events Arteriovenous Fistula Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-depression group

The Hamilton Rating Scale for Depression (HAMD) will be applied to assess the depressive status of all enrolled patients. This scale consists of 24 survey items, each with a score of 0-4. Patients will be assigned to the nondepression group if their HAMD score was \<8.

depression

Intervention Type OTHER

The score of Hamilton Rating Scale for Depression (HAMD) is ≥8

Depression group

Patients will be assigned to the depression group if their score was ≥8.

depression

Intervention Type OTHER

The score of Hamilton Rating Scale for Depression (HAMD) is ≥8

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

depression

The score of Hamilton Rating Scale for Depression (HAMD) is ≥8

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients had undergone dialysis treatment for more than 3 months, and their medical status was stable at the time of enrollment, with an expected survival period of more than 1 year

Exclusion Criteria

* (1) with communication disorders or mental illness other than depression; (2) a combination of cirrhosis, lymphoma, thrombocytopenic purpura, or other diseases that significantly affect platelet function; (3) complicated with malignant tumors, tuberculosis, severe heart failure, and unstable medical conditions; (4) inability or unwillingness to cooperate with researchers.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No